You are here

  • Home
  • Archive
  • Volume 3, Issue 2
  • Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1

Citation Tools

Article menu

Download PDFPDF

Psoriatic arthritis
Original article
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Coates LC, Kishimoto M, Gottlieb A, et al
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
RMD Open 2017;3:e000567. doi: 10.1136/rmdopen-2017-000567